Denosumab (Prolia® y Xgeva®). Riesgo de necrosis del canal auditivo externo. MHRA. ANMAT.

by Colfar | agosto 31, 2017 12:43 pm

Farmacovigilancia. Denosumab

Source URL: https://colfarsfe.org.ar/2017/08/31/denosumab-prolia-y-xgeva-riesgo-de-necrosis-del-canal-auditivo-externo-mhra-anmat/

---